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Nontuberculous mycobacteria (NTM) are widely disseminated in the environment and an emerging
cause of infectious diseases worldwide. Their remarkable natural resistance to disinfectants and anti-
biotics and an ability to survive under low-nutrient conditions allows NTM to colonize and persist in
man-made environments such as household and hospital water distribution systems. This overlap be-
tween human and NTM environments afforded new opportunities for human exposure, and for
expression of their often neglected and underestimated pathogenic potential. Some risk factors pre-
disposing to NTM disease have been identiﬁed and are mainly associated with immune fragilities of the
human host. However, infections in apparently immunocompetent persons are also increasingly re-
ported. The purpose of this review is to bring attention to this emerging health problem in Portugal and
Brazil and to emphasize the urgent need for increased surveillance and more comprehensive epidemi-
ological data in both countries, where such information is scarce and seriously thwarts the adoption of
proper preventive strategies and therapeutic options.
© 2015 Elsevier Ltd. All rights reserved.Contents
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The genus Mycobacterium is notorious for including the patho-
gens accountable for two of the most ancient diseases known to
humankind, leprosy and tuberculosis (TB), responsible for count-
less deaths and afﬂiction through human history [1,2]. However,
since Hansen's discovery of Mycobacterium leprae in 1873 and
Koch's discovery ofMycobacterium tuberculosis nine years later, the
list of described mycobacterial species has grown and currently
counts with 170 species and subspecies (www.bacterio.net/
mycobacterium.html) (Figure 1). These less known and often
neglected mycobacteria, collectively called nontuberculous myco-
bacteria (NTM), are ubiquitous environmental saprophytes and
increasingly regarded as opportunistic human pathogens [6].
Although only a few NTM species are familiar to clinicians and
commonly associated with human infection, many of the species
described over the last two decades are regarded as potentially
pathogenic (Figure 1) [7,8]. The success of NTM both as ubiquitous
saprophytes and as opportunistic pathogens can in part be
explained by their natural resilience to stress conditions such as
desiccation, nutrient starvation, extreme temperatures and pH, and
antimicrobials resistance [9,10]. Along with their bioﬁlm-forming
capabilities, these characteristics render NTM particularly well-
suited for the colonization of artiﬁcial environments such as chlo-
rinated water supply networks, where they can proliferate and gain
advantage over their chlorine-sensitive competitors [9,11,12].
Mycobacteria are traditionally divided into slowly-growing
mycobacteria (SGM) and rapidly-growing mycobacteria (RGM)
based on growth rate and although historically the species within
the SGM group are the ones that have almost always been asso-
ciated with disease, the signiﬁcant numbers of nosocomial in-
fections caused by RGM have changed this perception [13]. In fact,
convincing evidence indicates that the numbers of NTM infections
caused by both SGM and RGM species are rising worldwide
although the lack of systematic reporting in most countries still
renders it difﬁcult to establish deﬁnitive conclusions concerning
their true global incidence [14e17]. Several hypotheses have been
proposed to explain this rising trend, notably the increasing
overlap of human and mycobacterial habitats (e.g., water distri-
bution systems), increased numbers of NTM in drinking water due
to changes in water quality and wider adoption of disinfection
regimens that promote selection for these organisms, greater
physician awareness of NTM as a possible cause of infections
leading to more cases being diagnosed and reported, and the
greater prevalence of some predisposing factors in the human
population [18]. Risk factors for NTM disease that have been
identiﬁed so far include: (i) lowered immunocompetence due to
HIV infection, cancer, chemotherapy, use of immunosuppressive
drugs following transplants or ageing-dependent immunose-
nescence; (ii) underlying lung conditions such as chronic
obstructive pulmonary disease, cystic ﬁbrosis, lung damage due to
occupational exposure, to smoking, to prior tuberculosis or other
lung disease; (iii) genetic factors, namely mutations in the cysticﬁbrosis transmembrane conductance regulator gene or in the a-1-
antitrypsin gene [19].
In this review, we will focus on the information available about
the current status of NTM infections in Portugal and Brazil, two
countries for which epidemiological data is still scarce and whose
historically high TB burdens [20] have for many years over-
shadowed the role of NTM in human disease. In 2013, Portugal had
a tuberculosis incidence rate of 26 cases per 100,000 population
while in Brazil the incidence rate was 46 per 100,000 population
[20]. In order to shed light into this emerging health problem, we
conducted a survey of the available literature on NTM infections in
Portugal and Brazil by searching PubMed, Web of Science, Google
Scholar, SciELO and Lilacs databases between December 2014 and
February 2015. The keywords mycobacter*, atypical or non-
tuberculous or non-tuberculous, Portugal or Brazil, infection or
outbreak or disease or isolation were used and the search was
repeated in Portuguese. Reports in languages other than English or
Portuguese and with ambiguous or absent geographical informa-
tion were excluded, no other exclusion criteria were employed.
2. Pulmonary NTM infections
Pulmonary disease is a commonmanifestation of NTM infection
and has been the focus of many recent reviews [21e24]. However,
only a few studies have investigated the epidemiology of pulmo-
nary NTM (PNTM) infections in Portugal and Brazil (Table 1)
[25e44]. In addition many of these studies have important limi-
tations as will be discussed later in this section. Two of these sur-
veys, conducted in the Greater Lisbon Area, covering the period
between 2005 and 2009, independently found NTM to account for
approximately 12% of all isolates from patients diagnosed with
mycobacterial disease, leaving the remaining 88% of the cases to
species of the Mycobacterium tuberculosis complex [25,26]. In
Brazil, the reported incidence rates differ signiﬁcantly between
different states, periods, and population samples. In the states of
Bahia, Para and Piauí, 8% of patients presenting symptoms
compatible with pulmonary TB were actually found to be infected
with NTM [39,43,44]. In the state of S~ao Paulo, where most Bra-
zilian studies have been conducted, the percentage of NTM infec-
tion among patients suspected of mycobacteriosis has been
reported to be around 20% [32,33,37,34] and in the state of
Rondo^nia one study also found a similar result [41]. Agertt and co-
workers reported 33% of NTM in Rio Grande do Sul but the inclusion
of non-clinically relevant samples of both pulmonary and extrap-
ulmonary origin probably led to an overestimation and does not
reﬂect the true incidence of PNTM disease [42].
These results illustrate the relevance of PNTM infections as a
public health problem in Portugal and Brazil, but because PNTM
disease cases are not of mandatory notiﬁcation, the true incidence
in both countries remains indeterminate due to lack of more
comprehensive data. Even in countries with a high incidence of TB,
it is important to be aware that a signiﬁcant proportion of myco-
bacterial pulmonary disease cases are in fact caused by NTM,
Figure 1. Phylogenetic tree of the Mycobacterium genus. Phylogenetic analyzes were performed using MEGA6 [3]. Trees were created using the maximum-likelihood algorithm [4],
based on a comparison of all available (GeneBank) 16S rRNA gene sequences of type strains of genus Mycobacterium (<900 b.p. partial sequences of M. minnesotense and
M. lepraemurium were omitted) plus strains M. canettii, M. mungi and M. orygis from the Mycobacterium tuberculosis complex. The clinically relevant ‘Mycobacterium avium subsp.
hominissuis’ is included here under the Mycobacterium avium subsp. avium designation. Names in red indicate strains described as agents of infections in humans. Symbol (C)
indicates node branches conserved when tree was reconstructed using neighbor-joining algorithm [5]. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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drugs and regimens (isoniazid, rifampicin, pyrazinamide, and
ethambutol) [45]. As an example, standard therapy for the Myco-
bacterium avium complex pulmonary disease is macrolide-based,
requiring the combination of clarithromycin or azithromycin with
ethambutol and a rifamycin, and in some cases an aminoglycoside
is also recommended [46]. Although less reliably, macrolides are
also generally recommended against Mycobacterium abscessus
pulmonary disease, combined with one or more parenteral agents
between amikacin, cefoxitin and imipenem [47]. As these examplesillustrate, failure to identify the infectious agent to the species level
may lead to inappropriate antibiotic regimens with consequent
therapeutic failures and possibly fostering the emergence of drug
resistance trends [26,38,48,49].
It should be noted that NTM isolation from patients with
symptoms of lung infectious disease does not in itself mean that
the mycobacteria isolated are the source of the disease, as many
mycobacteria are known to transiently or persistently colonize
patients with an underlying lung condition without necessarily
contributing to disease progression. Thus, the American Thoracic
Table 1
Summary of the characteristics and results of the studies concerning pulmonary nontuberculous mycobacterial (NTM) infections in Portugal and Brazil included in the present review.
Geographic
range
Study period Target population/Study characteristics NTM frequency among total
mycobacterial isolates (%)
No. NTM
isolates
Most common species (frequency) Less common species Reference
Lisbon,
Portugal
2008e2009 HIV-negative patients with lung
infection/no conﬁrmation of NTM
infection after isolation
11,4 58 M. avium complex (22%), M. fortuitum
(14%), M. gordonae (12%), M. kansasii
(10%), M. chelonae (9%)
M. peregrinum, M. abscessus, M. szulgai,
M. triplex, M. mucogenicum, M.
lentiﬂavum, M. simiae
[25]
2005e2007 Patients with presumptive active
mycobacteriosis/no conﬁrmation of
NTM infection after isolation
12,6 149 M. avium complex (34%), M. gordonae
(15%), M. fortuitum (9%), M. kansasii
(9%), M. chelonae (7%), M. xenopi (6%)
M. peregrinum, M. abscessus, M.
mucogenicum, M. scrofulaceum, M.
malmoense, M. simiae, M. lentiﬂavum, M.
heckeshornense, M. celatum
[26]
Northern
Portugal
2008e2012 Patients with respiratory sample
positive for NTM/conﬁrmation of NTM
infection
NA 378 M. avium complex (63%), M. gordonae
(11%), M. peregrinum (9%), M. chelonae
(7%), M. kansasii (3%), M. abscessus (3%)
M. scrofulaceum and others [27]
Subset of conﬁrmed PNTM disease
cases
68 M. avium complex (94%), M. kansasii
(3%), M. xenopi (3%)
M. scrofulaceum and M. abscessus
2005e2011 Patients with conﬁrmed PNTM disease NA 11 M. avium complex (55%) M. kansasii, M. gordonae, M. fortuitum,
M. peregrinum, M. scrofulaceum
[28]
2007e2010 Patients with respiratory sample
positive for NTM/conﬁrmation of NTM
infection
NA 108 M. avium complex (40%), M. gordonae
(34%)
Others [29]
Subset of conﬁrmed PNTM disease
cases
23 M. avium complex (73%), M. kansasii
(9%), M. gordonae (9%), M. xenopi (9%),
M. genavense (9%)
e
1997e2004 HIV-negative patients with respiratory
sample positive for NTM/conﬁrmation
of NTM infection
NA 102 M. avium complex (47%), M. fortuitum
(21%), M. gordonae (19%), M. kansasii
(7%), M. chelonae (2%), M. peregrinum
(2%)
M. abscessus, M. scrofulaceum, M. terrae [30]
Subset of conﬁrmed PNTM disease
cases
16 M. avium complex (75%), M. kansasii
(13%), M. fortuitum (6%), M. abscessus
(6%)
e
Multistate,
Brazil
1994e1999 Patients with presumptive
mycobacteriosis/conﬁrmation of NTM
infection
NA 431 M. avium complex (38%), M. kansasii
(14%), M. fortuitum (14%), M. abscessus
(7%), M. terrae (4%)
M. scrofulaceum, M. gordonae, M.
peregrinum, M. szulgai, M. chelonae, M.
ﬂavescens, M. asiaticum, M.
nonchromogenicum, M. mucogenicum,
M. malmoense, M. marinum
[31]
Subset of conﬁrmed PNTM disease
cases
NA 64 M. avium complex (53%), M. kansasii
(20%), M. fortuitum, M. abscessus (6%),
M. chelonae (6%), M. scrofulaceum (4%),
M. szulgai (3%)
e
S~ao Paulo
state, Brazil
2009e2010 Patients with clinical sample positive
for NTM/no conﬁrmation of NTM
infection
23 84 M. avium complex (45%), M. fortuitum
(10%), M. abscessus (10%), M. kansasii
(8%), M. gordonae (6%), M. ﬂavescens
(4%)
M. xenopi, M. szulgai, M. parmense, M.
chelonae, M. lentiﬂavum, M. simiae, M.
sherrisii, M. mucogenicum, M. kubicae, M.
alvei
[32]
2000e2004 HIV-positive patients with symptoms of
pulmonary tuberculosis
24,2 42 M. avium complex (14%), M. fortuitum
(14%), M. kansasii (12%)
M. chelonae, M. shimodei, M. triviale, M.
terrae, M. peregrinum
[33]
1996e2005 Patients with respiratory sample
positive for NTM/conﬁrmation of NTM
infection
24,4 271 M. avium complex (56%), M. gordonae
(12%), M. fortuitum (8%), M. terrae (3%),
M. chelonae (3%)
M. kansasii, M. abscessus, M.
scrofulaceum, M. peregrinum, M.
shimodei, M. malmoense, M. neoaurum,
M. ﬂavescens, M. interjectum
[34]
Subset of conﬁrmed PNTM disease
cases
35 M. avium complex (63%), M. fortuitum
(11%), M. gordonae (9%), M. chelonae
(6%)
M. kansasii, M. abscessus, M. malmoense
2000e2005 Patients with symptoms of pulmonary
tuberculosis/conﬁrmation of NTM
infection
NA 194 M. kansasii (34%), M. avium complex
(17%),M. fortuitum (13%),M. peregrinum
(2%), M. gordonae (2%)
M. nonchromogenicum, M. chelonae, M.
terrae, M. triviale, M. ﬂavescens, M.
bohemicum, M. shimodei, M. lentiﬂavum
[35]
1991e1997 Patients with respiratory sample
positive for NTM/no conﬁrmation of
NTM infection
NA 600 M. avium complex (51%), M. kansasii
(21%), M. gordonae (12%), M. fortuitum
(5%), M. terrae (3%)
M. chelonae, M. xenopi, M. szulgai [36]
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have issued diagnostic criteria to aid diagnosis of PNTM disease
cases and distinguish them from simple colonization [45]. Clinical,
radiographic and microbiological evidence are needed, as well as
exclusion of other disorders such as TB. Unfortunately, for a great
proportion of the published studies on PNTM these criteria and
clinical relevance of NTM isolation were not assessed. However,
some of these studies were relevant for the present review and
were likewise included, although special care was taken to pro-
vide the accurate information to the reader. Furthermore, the
population analyzed and type of clinical specimens included in
each study varies widely, rendering comparisons between the few
available studies difﬁcult to draw. Nevertheless, some patterns
emerge from a careful analysis of the literature, with some species
being particularly prominent. Table 2 ranks the species isolated in
Portugal and Brazil according to their frequency of isolation across
all the studies included in this review, revealing M. avium com-
plex, Mycobacterium kansasii, Mycobacterium gordonae, Mycobac-
terium fortuitum and M. abscessus as the most consistently
frequent species when both countries are considered. Next, the
NTM most frequently isolated from respiratory samples in
Portugal and Brazil are presented and their clinical relevance
brieﬂy discussed.
2.1. Pulmonary infections with Mycobacterium avium complex
(MAC)
TheM. avium complex harbors the speciesMycobacterium avium
(which itself includes the subspecies M. avium subsp. avium,
‘M. avium subsp. hominissuis’, M. avium subsp. paratuberculosis and
M. avium subsp. silvaticum [50,51]), Mycobacterium intracellulare,
Mycobacterium chimaera, Mycobacterium colombiense, Mycobacte-
rium arosiense, Mycobacterium vulneris, Mycobacterium marseil-
lense, Mycobacterium bouchedurhonense and Mycobacterium
timonense (Figure 1). In humans, ‘M. avium subsp. hominissuis’,
M. intracellulare and M. chimaera seem to be the most relevant
opportunistic pathogens of the complex. These are the most
frequently isolated mycobacteria in Portugal and Brazil, even
though most studies do no not attempt to distinguish between the
different species and subspecies of MAC. The frequency of MAC
among mycobacterial isolates shows a lot of variation between
studies, but is often around 50%. In Portugal, it seems to be more
common in the Northern region, with frequencies ranging from
55% to 75% of all NTM isolates [27e30], than in Lisbon, where it has
been reported to be below 35% [25,26], although data are limited.
One consistent ﬁnding across studies that attempt to distinguish
disease cases within the sampled population is that MAC isolation,
unlike isolation of other species such asM. gordonae, is signiﬁcantly
associated with NTM disease [29,31,34]. This highlights the clinical
relevance of this documented and often deadly human pathogen
[52]. MAC lung disease is known for its high treatment failure rates
and poor outcome, mainly due to its relative resistance to chemo-
therapy and to a frustrating lack of correlation between in vitro
susceptibility results and in vivo clinical responses to tested anti-
biotics [21]. This lack of correlation is also observed for other NTM
species and has been attributed to innate resistance mechanisms,
differences in the metabolic state of mycobacteria in vitro and
in vivo, and to laboratory technical difﬁculties with drug suscepti-
bility assays [46,47].
2.2. Pulmonary infections with Mycobacterium kansasii
Mycobacterium kansasii is the second NTM species most
frequently isolated from respiratory samples in Brazil. In two
studies conducted in S~ao Paulo and Rio de Janeiro it was actually
Table 2
Rank order of the species of NTM isolated from clinical samples in Portugal and Brazil according to their frequency of isolation in all pulmonary NTM infection studies reviewed.
A total of 806 NTM isolates in Portugal and 3781 in Brazil were considered.
Portugal Brazil
M. avium complex 49% M. avium complex 48%
M. gordonae 16% M. kansasii 17%
M. fortuitum, M. peregrinum 6% M. fortuitum 7%
M. kansasii, M. chelonae 5% M. gordonae 6%
M. abscessus 3% M. abscessus 5%
M. xenopi 2% M. chelonae 3%
M. scrofulaceum 1% M. terrae complex, M. simiae complex 2%
M. mucogenicum, M. szulgai, M. triplex, M. lentiﬂavum,
M. simiae complex, M. genavense
<1% M. scrofulaceum, M. szulgai, M. peregrinum, M. xenopi,
M. ﬂavescens, M. marinum
<1%
M. malmoense, M. heckeshornense,
M. celatum, M. terrae complex
0.1% M. shimodei, M. triviale, M. asiaticum, M. lentiﬂavum, M. malmoense,
M. nonchromogenicum, M. celatum, M. smegmatis, M. parmense,
M. gilvum, M. mucogenicum, M. genavense, M. parascrofulaceum,
M. moriokaense, M. holsaticum, M. tuscicae, M. phlei, M. novocastrense,
M. porcinum, M. bohemicum, M. interjectum, M. neoaurum, M. alvei,
M. kubicae, M. sherrisii
0.1%
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pulmonary disease [35,40]. A multi-country survey covering the
period from 1991 to 1996 reported no M. kansasii isolates in
Portugal, while in Brazil 12% of the NTM analyzed belonged to this
species [53]. The scenario in Portugal seems to have changed since
then, as all Portuguese studies considered in the present review
report the isolation of M. kansasii strains, although still with much
lower frequency when compared with Brazil. Despite being a
clinically relevant NTM species and a common cause of pulmonary
infection, M. kansasii is often considered the most easily treatable
NTM pathogen, as it is generally susceptible to common antitu-
berculous drugs and shows a good correlation between in vitro
susceptibility tests and clinical response [21,45]. However, the
possibility of emergence of additional or increasingly resistant
strains should not be discarded. As an example, although
M. kansasii is reportedly sensitive to ethambutol [45], Telles and co-
workers found a strikingly high ethambutol-resistance frequency
in clinical relevant isolates from S~ao Paulo [54].
2.3. Pulmonary infections with Mycobacterium abscessus
The isolation of Mycobacterium abscessus from respiratory
samples is generally not as frequent as MAC andM. kansasii, but the
threat posed by an M. abscessus pulmonary infection is often more
serious and deserves particular attention. M. abscessus comprises
two different subspecies, namelyM. abscessus subsp. abscessus and
M. abscessus subsp. bolletii, which has also recently included
Mycobacterium massiliense [55]. Members of this species are
remarkably resistant to chemotherapy and have been referred to as
an “antibiotic nightmare” [56] for which there are no reliable
antibiotic regimens recommended [45]. Genomic analyses revealed
unique features and genetic resources that render them one of the
most divergent species of the genus, which also helps explaining
and translates into particular physiological trends [10]. In Rio de
Janeiro, Mello and co-workers followed 174 patients with PNTM
disease and among 12 NTM species involved, the lowest cure rate
was observed among M. abscessus infection cases, basically related
to the severe patterns of resistance of this strain [40]. Another study
conducted in Piauí in 2007 with 9 patients with NTM disease,
revealed that two were infected with M. abscessus. Both suffered
treatment failures and one died 5 years after the diagnosis [43].
2.4. Pulmonary infections with Mycobacterium fortuitum
Mycobacterium fortuitum was initially isolated in Brazil in 1938
and the subsequent isolates were later classiﬁed as M. fortuitumsubsp. fortuitum and M. fortuitum subsp. acetamidolyticum [57,58].
Commonly found in respiratory samples from Portugal and Brazil,
the isolation of M. fortuitum does not seem to be as clinically sig-
niﬁcant as the isolation of MAC,M. kansasii andM. abscessus. Often,
it is merely indicative of transient colonization in patients with an
underlying lung disease and does not progress even without anti-
biotic therapy directed at M. fortuitum [59]. However, it can cause
pulmonary disease in humans, particularly in patients with
gastroesophageal disorders [45]. Among the studies conducted in
Portugal, there is at least one described case of lung disease caused
byM. fortuitummeeting the ATS/IDSA criteria in a patient who had
to receive speciﬁc antibiotic treatment based on in vitro suscepti-
bility tests [28]. In S~ao Paulo, Pedro and co-workers found 4 cases
of conﬁrmed M. fortuitum lung infection [34]. Another study con-
ducted in Rio de Janeiro identiﬁed 11 casesmeeting the ATS criteria,
of which only 5 were successfully cured [40].
2.5. Pulmonary infections with Mycobacterium gordonae
Ubiquitous in the environment and in tap water,Mycobacterium
gordonae is isolated very frequently from respiratory samples but
rarely associated with disease, being regarded more as a contami-
nant than as a pathogen [45,60]. Isolates of this species have been
identiﬁed in all Portuguese and in most Brazilian studies dealing
with NTM respiratory isolates, reaching frequencies of over 30% of
all NTM isolated in some cases [29,43]. It is more frequently isolated
in Portugal than in Brazil (Table 2). When clinical relevance is
assessed, though, most M. gordonae isolates are found not to be
associated with disease. Nevertheless, M. gordonae pulmonary
disease is not unheard-of even in immunocompetent individuals
[60] and some cases in Portugal and Brazil have been reported. In
Portugal, Campainha and co-workers identiﬁed 2 cases of pulmo-
nary disease caused by M. gordonae [29]. In Brazil, 2 studies con-
ducted in 2 different states reported 3 cases of M. gordonae lung
disease each [43,34]. The 3 cases reported by Bona and co-workers
were successfully treated with clarithromycin.
2.6. Pulmonary infections with other less common NTM species
In addition to the aforementioned NTM, 36 other species/com-
plexes have been isolated from clinical samples in Portugal and
Brazil, albeit less frequently (Table 2). Of these, only 15 are
considered clinically relevant: Mycobacterium asiaticum, Mycobac-
terium celatum, Mycobacterium chelonae, Mycobacterium ﬂavescens,
Mycobacterium genavense, Mycobacterium lentiﬂavum, Mycobacte-
rium malmoense, Mycobacterium moriokaense, Mycobacterium
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complex, Mycobacterium smegmatis, Mycobacterium szulgai, Myco-
bacterium terrae complex andMycobacterium xenopi (Table 1). Two
other NTM species deserve special mention because they were
recently discovered and ﬁrst described in respiratory specimens
from Brazilian patients with lung disease. In 2013, Ramos and co-
workers described Mycobacterium fragae, closely related to
M. celatum, from 3 clinical isolates of a Ceara patient with lung
infection [61]. Even more recently, Fusco da Costa and co-workers
described a new species within the M. simiae complex, which ap-
pears to be particularly prevalent in the state of Para and was
denominated Mycobacterium paraense [62].
2.7. NTM pulmonary infection in cystic ﬁbrosis patients
NTM are increasingly recognized as clinically relevant infec-
tious agents in cystic ﬁbrosis (CF) patients, colonizing and
infecting their lungs and capable of signiﬁcantly affecting
morbidity and mortality [49,63,64]. Worldwide, NTM isolation in
respiratory samples has been reported in 6e22% of patients with
CF, with MAC and M. abscessus together accounting for over 90%
of the cases [63]. It should be noted that in many cases a transient
or persistent NTM colonization in CF patients does not progress
to active pulmonary disease [64]. In Brazil, at least two studies
have investigated this problem, one conducted in adults and the
other in children. Paschoal and co-workers studied a population
of adult CF patients with a less severe phenotype of the disease
and found a colonization by NTM in 11% of the patients [65].
However, none of the patients were diagnosed with NTM disease
and speciﬁc drug therapy was not prescribed. More recently,
Ca^ndido and co-workers reported a NTM frequency of 8% in CF
children and performed species identiﬁcation and antibiotic
susceptibility tests with the isolated mycobacteria [66].
M. abscessus group species predominated followed by MAC and
M. fortuitum. The antibiotic susceptibility proﬁles resulting from
this study are alarming, with over 97% of the isolates being
resistant to 5 or more drugs speciﬁcally used for mycobacterial
infections, and one of the patients from whom one of these
multidrug-resistant strains was isolated eventually developed
PNTM disease without resolution to the date the article was
elaborated [66].
3. HIV infection and NTM disseminated disease
The tight link between HIV infection and TB is widely known
[67], but NTM also pose a serious threat and are a common cause
of disease in AIDS patients [68]. NTM infection in AIDS patients
may be present in the form of pulmonary disease, and it should
be noted that many of the studies cited in section 2 include
mixed samples of HIV-positive and HIV-negative persons. How-
ever, interpretation of NTM isolation from respiratory samples of
HIV-positive patients requires additional considerations. Firstly,
some species that are generally considered nonpathogenic and
whose isolation from immunocompetent hosts is usually not
clinically relevant have been associated with disease in HIV-
infected persons [45]. Secondly, in the absence of evidence of
pulmonary disease, isolation of NTM from respiratory samples of
AIDS patients may indicate or foretell a case of NTM disseminated
disease [45].
Diagnosis of NTM disseminated disease is usually performed
through culture of clinical samples from sites presumed to be
sterile of the patient, such as blood, bone marrow or lymph nodes
[45]. In Portugal, the only data of NTM isolation from presumably
sterile sites was reported by Couto and co-workers, who identiﬁed
14 MAC and one M. simiae isolates from blood cultures of patientswith symptoms of mycobacteriosis [26], although the HIV-status
of the patients was not reported. MAC (speciﬁcally ‘M. avium
subsp. hominissuis’ in the vast majority of cases) is indeed the
most frequently reported NTM associated with disseminated
disease in HIV-positive patients, and the results from Brazilian
studies are also consistent with this observation [69e71]. Other
species isolated from presumed sterile sites of AIDS patients in
these studies, and which were conﬁrmedly involved in dissemi-
nated disease, wereM. kansasii andM. scrofulaceum.M. lentiﬂavum
has also been isolated from blood of a patient with NTM
disseminated disease in Brazil who was also co-infected with
M. avium [72], and a fatal case of M. simiae disseminated disease
has also been described [73].
4. Post-surgical infections with rapidly-growing
mycobacteria
Infection by RGM following invasive procedures has been
described worldwide and increasingly in Brazil [74e76] leading to
its recognition as a serious health problem by the Brazilian National
Agency for Sanitary Surveillance (Age^ncia Nacional de Vigila^ncia
Sanitaria - ANVISA) [76]. Inadequate decontamination of surgical
equipment, emergence and dissemination of disinfectant-resistant
strains and their presence in antimicrobial solutions as well as lack
of appropriate infection-control measures are very often the source
of severe post-surgical infection outbreaks [77]. Several studies
have focused on this issue in Brazil and detailed descriptions of
RGM surgical-site infection outbreaks can be found in the litera-
ture. Environmental investigation following major outbreaks is
increasingly performed to identify the source of infection and
inform the adoption of preventive measures, although in a few
cases only after the clinics have adopted the adequate measures
and changed practices to contain the outbreaks, including thorough
cleaning and disinfection of the more obvious potential sources of
contamination, resulting in the source of infection never being
conclusively identiﬁed [78,79].
Unlike PNTM disease, NTM post-surgical infection cases are of
compulsory notiﬁcation in Brazil since 2009 due to the occurrence
of outbreaks of unprecedented magnitude across the country,
which led Brazilian health authorities to recognize these infections
as a national health emergency [80]. In this section, the invasive
health or cosmetic procedures most often associated with RGM
post-surgical infections and outbreaks in Brazil over the last years
are reviewed.
4.1. Infectious keratitis with NTM
Infectious mycobacterial keratitis is a rare complication of laser-
assisted in situ keratomileusis (LASIK), a commonly used vision
correction surgical procedure that enhances the refractive condi-
tion of the cornea [81]. Several cases and outbreaks of post-LASIK
mycobacterial infection have been described in Brazil, mainly
involvingM. chelonae. In fact, the ﬁrst detailed descriptions of RGM
surgical infections in Brazil were associated with this procedure
[82]. M. chelonae was responsible for the 2 largest reported out-
breaks. The ﬁrst occurred in 1999 at a private clinic in Rio de
Janeiro, with 65 eyes diagnosed with infectious keratitis following
LASIK, of which 16 were conﬁrmed to be positive for M. chelonae
[83]. One year later another M. chelonae-caused keratitis outbreak
emerged at a private clinic in S~ao Paulo, affecting 10 patients
treated by the same surgeon. A possible source of infection was
identiﬁed during the investigation that followed, with evidence
pointing to the portable steamer used to clean the microkeratome,
whose water was found to be contaminated with M. chelonae [84].
In 1998, two patients who underwent LASIK at a private clinic in Rio
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mycobacteriawas also responsible for 2 other cases at a clinic in S~ao
Paulo in 1999 and 2000 [83]. Although ﬂuoroquinolones are often
the antibiotics of choice for corneal infections, a subsequent
investigation found thatM. abscessus andM. chelonae isolates from
these Brazilian outbreaks were highly resistant to this class of an-
tibiotics, emphasizing the importance of early diagnosis of NTM-
caused infections to expand therapeutic options [85]. Mycobacte-
rium immunogenumwas also implicated in an outbreak of keratitis
in S~ao Paulo involving 5 patients who underwent LASIK in 2003
[78].
4.2. NTM infection in prosthetic valve endocarditis
Prosthetic valve endocarditis (PVE) caused by NTM is a rare but
documented complication of valve implant surgeries [86]. In S~ao
Paulo, a cluster of 13 implanted patients who developed PVE caused
by M. chelonae has recently been reported [87]. All patients had
received porcine valve implants between 1997 and 2002 and all the
valves were from the same manufacturer. Investigation of 6 non-
implanted and supposedly sterile valves revealed contamination
with M. chelonae, which led the hospital to discontinue their use.
These cases were not the ﬁrst ofM. chelonae PVE described in Brazil
[88] and persistence of viable M. chelonae in porcine valves after
chemical treatment for use as biological prosthetic valves had
already been investigated and discussed in the Brazilian literature
[89].
4.3. Post-mammoplasty NTM infections and the Campinas'
outbreak
Between 2002 and 2004, an outbreak of post-mammoplasty
surgical-site infections emerged in the city of Campinas, state of
S~ao Paulo, affecting 35 patients. All but one of the 12 isolates
recovered were identiﬁed as M. fortuitum. During this period, 5
patients who underwent mammoplasty surgery in other cities and
one patient who had abdominal wall plastic surgery in Campinas
were also diagnosed with M. fortuitum surgical-site infections,
although molecular typing results suggested that this was a
polyclonal outbreak with no signs of clone dissemination between
hospitals [90]. The source of infection was never conclusively
identiﬁed, but the investigation that followed raised suspicions
regarding the use of reusable sizers, commonly employed by
surgeons to estimate the volume of the deﬁnitive implant prior to
its application [91]. This led ANVISA to temporarily suspend the
use of the device [92] until the manufacturers introduced the
necessary improvements, one of the measures that likely
contributed to the elimination of post-mammoplasty NTM in-
fections in the affected hospitals the year following the outbreak
[91]. In fact, M. fortuitum is the NTM most frequently associated
with post-mammoplasty infections in Brazil, responsible for more
than half of the cases reported to the health surveillance system
until 2009, followed by M. abscessus [93]. Other NTM infectious
agents have been implicated namely Mycobacterium porcinum
which was responsible for one of the Campinas' outbreak cases
[90]. In 2010 the ﬁrst case of Mycobacterium wolinskyi breast
infection in Brazil was reported [94]. Cases involving
M. peregrinum and M. smegmatis have also been reported [93]. The
most recent ANVISA report on RGM infections shows that post-
mammoplasty mycobacterial infections are still an important
health problem in Brazil despite the preventive measures enforced
by ANVISA in the aftermath of the Campina's outbreak, with 85
cases reported between 2010 and 2014, including an outbreak in a
Bahia clinic in 2013 [76].4.4. Epidemic of Mycobacterium massiliense surgical-site infections
in Brazil
Between 2004 and 2008, several Brazilian states faced nosoco-
mial outbreaks involving a particular strain of Mycobacterium
massiliense (recently reclassiﬁed as M. abscessus subsp. bolletii),
often referred to as the BRA100 clone [55,95e97]. This nationwide
epidemic began with the Belem outbreak in the state of Para and
involved 298 patients who had undergone laparoscopic surgeries in
16 different private hospitals in the city of Belem. A sample of 58
isolates were analyzed by rpoB sequencing and PFGE molecular
typing and identiﬁed as a single clone of M. massiliense [98]. As
soon as the Belem outbreak started to subside in the middle of
2005, an outbreak of surgical-site infections caused by the same
strain ofM.massiliense emerged in the state of Goias, with 121 cases
of patients diagnosed with NTM infection following laparoscopic
and arthroscopic surgeries at 7 private hospitals in the city of
Goia^nia. Molecular typing and rpoB sequencing of 18 sampled iso-
lates revealed the unexpected link with the epidemic isolates from
the distant city of Belem [99].
In the state of Rio de Janeiro, this same strain caused the largest
outbreak of RGM postsurgical infections recorded to date in Brazil,
with over 1000 patients possibly affected and 63 public and private
hospitals involved [95]. Between August 2006 and July 2007, 1051
possible cases were reported in this state of which 172 were
conﬁrmed by laboratory techniques. All patients had undergone
video-assisted surgery. Randomly selected isolates were analyzed
by rpoB and hsp65 sequencing and PFGE ﬁngerprinting, conﬁrming
their clonal identity with isolates from the Belem and Goia^nia
outbreaks [95]. Antimicrobial susceptibility tests revealed suscep-
tibility to amikacin and clarithromycin and resistance to cipro-
ﬂoxacin and doxycycline, as well as a high glutaraldehyde tolerance
for BRA100 isolates [95,100]. This massive outbreak was followed
by another in the state of Parana, city of Curitiba, which lasted until
January 2008 and involved 131 surgical patients from 7 private
hospitals. Out of 39 isolates collected and analyzed, 36 were shown
to belong to the M. massiliense BRA100 clone [96]. Other 3 out-
breaks in the states of Espírito Santo, S~ao Paulo, and Rio Grande do
Sul were also found to be caused by this same strain [97].
All these outbreaks were associated with video-assisted sur-
geries involving the use of laparoscopic or arthroscopic equipment.
At the time, all hospitals and clinics involved were using the same
protocol for high-level disinfection of surgical equipment between
surgeries: immersion in 2% glutaraldehyde for at least 30 min.
While this procedure is effective in eliminating reference strains of
RGM, the BRA100 clone was found to be resistant to immersion in
2% glutaraldehyde for as much as 10 h [100]. This led the Brazilian
health surveillance agency to immediately suspend this practice
[80]. The glutaraldehyde-resistant phenotype in mycobacteria has
been associated with defects in porin expression [101] and could in
part account for the Brazilian M. massiliense epidemic. Further
research in the BRA100 clone also showed increased virulence and
in vivo pathogenicity of this strain when compared with a
glutaraldehyde-sensitive M. massiliense reference strain [102]. In
addition to this, inspections carried out by public health authorities
revealed that some of the hospitals involved were breaching
important protocols of infection control and prevention [99,103],
which may also have played a role in the epidemic.
A study conducted in Rio Grande do Sul in the aftermath of the
epidemic found that the BRA100 clone persisted in several hospi-
tals of the state after the major 2004e2008 outbreaks, causing
postsurgical infections and small outbreaks across the state at least
until 2011 [104]. Perhaps the most worrying ﬁnding of this study
was the resistance to clarithromycin shown by a signiﬁcant
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something that had not yet been reported for the BRA100 clone.
Surprisingly, a recent study found remarkable genetic similar-
ities between BRA100 epidemic isolates and M. massiliense isolates
involved in an outbreak of respiratory infections in a cystic ﬁbrosis
center in the UK [105,106], raising the intriguing and alarming
possibility of intercontinental dissemination of a particularly
disinfectant-resistant and virulent mycobacterial strain.
4.5. Cutaneous NTM infections due to non-surgical invasive
procedures
In addition to post-surgical infections by RGM, infections asso-
ciated with the use of invasive procedures for cosmetic or medical
purposes have also been described in Brazil and Portugal. In Brazil,
there have been several reports of mycobacterial infections and
outbreaks associated with mesotherapy, a popular treatment to
reduce localized fat performed in aesthetic clinics that consists of
intradermal or subcutaneous topical injections of pharmacological
substances. In 2000, the largest described outbreak involving NTM
infections and mesotherapy took place at a private clinic in S~ao
Paulo state, with 43 people diagnosed with cutaneous infections.
The infectious agent was identiﬁed as M. chelonae [83]. In 2002
there was another outbreak in a cosmetic clinic in the same state,
with 7 conﬁrmed cases ofM. abscessus skin infection. In both cases,
multiple mesotherapy sessions were reportedly performed with
solutions stored in multiuse vials, a factor that may have contrib-
uted to the outbreaks [83]. Concomitantly with the Belem
M. massiliense outbreak mentioned in section 4.4, a smaller
outbreak caused by another M. abscessus subsp. bolletii strain
affected 14 patients who underwent mesotherapy at a private clinic
also in Belem [98]. M. fortuitum has also been associated with
mesotherapy-acquired skin infections in S~ao Paulo and Bahia
[107,108]. Recently disclosed data reveals that over the last 4 years
(2010e2014) mesotherapy-associated RGM infections have
remained a concerning public health problem. Over this period, 63
cases were reported in Brazil, all involving illegal subcutaneous
injections of phosphatidylcholine in the form of Lipostabil® for
cosmetic purposes [76]. Worldwide, mesotherapy-associated NTM
infections have been traced to contaminated injectable solutions or
skin antiseptics and to inappropriate cleaning of injection devices
with nonsterile tap water, but no environmental source was iden-
tiﬁed in these Brazilian outbreaks [109,110].
Acupuncture is also a procedure for which association with
mycobacterial infections has been described worldwide. In Brazil,
Castro-Silva and co-workers described one case of an immuno-
suppressed kidney transplant patient who developed a cutaneous
Mycobacterium haemophilum infection after being prescribed with
acupuncture for pain relief [111]. Skin lesion sites matched needle
insertion sites perfectly, strongly suggesting inoculation during the
acupuncture sessions. The patient reported lack of infection control
measures by the acupuncture practitioner, namely that his skinwas
not cleaned prior to needle insertion and that the same reusable
needles were used multiple times during the session. In Portugal, a
case of M. fortuitum skin infection following acupuncture has also
been reported [112].
Although there are no reports of NTM infections associated with
tattooing in Portugal and Brazil, many cases and outbreaks of
tattoo-associated NTM skin infections have emerged over the last
decade, with reports from the USA, France, Germany, Spain, Scot-
land, Switzerland, Australia, Israel, Serbia and Thailand [113e116].
In almost all cases the source of infection was traced to the tattoo
ink or to tap water used for ink dilution, and the species involved
were M. chelonae, M. abscessus, M. haemophilum, M. fortuitum and
M. immunogenum [116].5. High-risk environmental isolation of NTM
The ubiquity of NTM in the environment and the very limited
evidence of human-to-human transmission seem to point to the
surrounding environment as the most likely source of human NTM
infection and colonization [19,106]. Tap water in particular seems to
be an important reservoir of these environmental species of
mycobacteria, which are highly resistant to chlorine disinfection
and thrive in showerhead bioﬁlms [11,12]. In Lisbon, the detection
of M. gordonae, M. intracellulare, M. kansasii and M. chelonae in the
municipal water distribution system has been reported [117].
Coincidently, these four species are also among the most frequently
isolated NTM in respiratory samples of Lisbon residents [25,26].
NTM isolation from hospital settings is also common and poses
a particularly serious risk for hospitalized patients, who are
frequently more vulnerable to these opportunistic pathogens.
Recognizing this threat, Restrepo and co-workers investigated
the presence of NTM in samples of tap water, antiseptic solutions
and surgical gloves from a university hospital of Manaus and
concluded that the hospital water distribution systemwas colonized
by several species of NTM. M. celatum and M. gordonae were the
most frequently isolated species, followed by M. intracellulare,
M. lentiﬂavum and Mycobacterium mucogenicum [118]. In a similar
study carried out at a S~ao Paulo hemodialysis center, Sartori and co-
workers isolated M. lentiﬂavum, M. gordonae, M. kansasii, Mycobac-
terium gastri and M. szulgai in its hydric system and suggested that
NTM bioﬁlms in the center's plumbing and inadequate water
decontamination processes were likely the source of the contami-
nation [119].M. lentiﬂavumwas particularly abundant and seemed to
persist and thrive in the hemodialysis center water system. Also in
S~ao Paulo, Souza and co-workers isolated NTM from exposed sur-
faces in the clinical environment of 2 health institutions and found
both potentially pathogenic and rarely pathogenic species, including
M. avium, M. fortuitum, M. kansasii, M. malmoense, M. lentiﬂavum,
M. simiae, M. mucogenicum, M. smegmatis, M. ﬂavescens, M. gastri,
M. genavense, Mycobacterium vaccae and, the most frequent,
M. gordonae [120]. In Portugal the lack of this type of environmental
investigation is even more conspicuous than in Brazil. In a pre-
liminary assessment we have recently isolated several drug resistant
NTM strains from surfaces of a Portuguese central hospital belonging
to the species M. gordonae, M. mucogenicum and Mycobacterium
obuense (our unpublished results). Alarmingly, susceptibility tests
revealed multidrug-resistant phenotypes to multiple classes of an-
tibiotics (>5 antibiotics recommended by Clinical & Laboratory
Standards Institute (CLSI) standards in addition to the 5 antibiotics
used for selective isolation of mycobacteria).
6. Future directions
The therapeutic challenges posed by opportunistic mycobac-
teria are a direct consequence of their unique physiology and
ecology, and will not be met without intensifying efforts into un-
derstanding their traits and ﬁnding new strategies for prevention
and treatment of NTM infections. Because tap water seems to be
one of the main routes of human exposure to NTM, reducing every-
day exposure to these pathogens is necessarily tied to reducing
their numbers in household and hospital plumbing premises.
Measures to achieve this have been proposed based on recent
research, including raising water heater temperature to 55 C and
improving aeration [6]. Treating most NTM infections is currently
an arduous task, limited by their intrinsic resistance to many
known antibiotics. New drugs are urgently needed, and while at-
tempts to test antibiotics developed forM. tuberculosis against NTM
have produced disappointing results [121,122], the same avenues of
researchmay be applied for the speciﬁc cases of NTM species. Some
D. Nunes-Costa et al. / Tuberculosis 96 (2016) 107e119116of these approaches include revealing and exploring novel targets
against which new drugs can be designed through combining
atomic-level analyses with protein chemistry and cell biology,
repurposing and re-engineering existing compounds, and ﬁnding
innovative immune-based strategies such as autophagy manipu-
lation [10,123,124].
7. Concluding remarks
The current status of NTM infections in Brazil is deﬁnitely
alarming while in Portugal it is largely and worryingly unknown
and severely underreported. In both countries, there is an urgent
need for more and better-planned epidemiological surveys and
for in-depth environmental investigations of NTM persistence in
water and inanimate surfaces of high-risk sites, healthcare set-
tings primarily. Even more critically, studies comparing environ-
mental isolation of NTM with spatially and temporally related
clinical cases of NTM infection are urgently required to better
understand and manage the real risks of NTM exposure in
different settings. The fact that the few existing studies already
show the isolation of so many NTM strains from healthcare set-
tings, some of which belonging to species often involved in
serious human infections, is a matter of increasing concern and
calls for the adoption of more effective and regular disinfection
protocols. Our preliminary results obtained with a set of multi-
drug resistant strains recently isolated from a Portuguese tertiary
hospital indicate that they are susceptible to common disinfec-
tants, reinforcing the importance of implementing proper and
regular disinfection procedures in NTM infection prevention. If
cost reduction policies continue to hinder the implementation of
adequate preventive measures in Portuguese hospitals and other
healthcare institutions, the situation can rapidly run out of con-
trol and reach massive proportions, as was the case with the
M. massiliense epidemic in Brazil.
In view of the therapeutic challenges posed by these opportu-
nistic mycobacteria, it is also essential to get a clearer picture of
antibiotic resistance proﬁles of NTM strains circulating in Portu-
guese and Brazilian hospitals. The unusually high and multiple
resistances to antibiotics and disinfectants are hallmarks of the
Mycobacterium genus, to which both intrinsic and acquired mech-
anisms contribute. Intrinsic drug resistance has been primarily
attributed to mycobacteria's lipid rich cell envelope which confers
low permeability to antibiotics and other chemotherapeutics
agents [125]. More recently, efﬂux mechanisms have also been
recognized as an important factor in the natural resistance of
mycobacteria as they play an important role in mediating the efﬂux
of drugs such as tetracycline, ﬂuoroquinolones and aminoglyco-
sides, among others [126e128]. Acquired drug resistance is
generally mediated by horizontal transfer of genetic elements
through plasmids, transposons or integrons. In M. tuberculosis,
which has been speciﬁcally studied in the context of drug resis-
tance/susceptibility, this type of resistance is caused mainly by
chromosomal spontaneous or induced mutations, favoring the se-
lection of resistant strains during sub-optimal drug therapeutic
regimens [129]. In some clinically relevant NTM species, such as
M. abscessus and M. fortuitum, an inducible mechanism of macro-
lide resistance has been found to confer in vivo acquired resistance
to this class of antibiotics in some strains without affecting in vitro
MIC values, which further complicates the already difﬁcult task of
choosing appropriate therapeutic schemes [21]. With no reliable
and clearly deﬁned antibiotic regimens and with a constantly
changing and increasingly complex scenario, NTM antibiotic
resistance surveillance is therefore mandatory in order to
comprehensively understand this emerging health threat and to
guide increasingly difﬁcult therapeutic decisions.Acknowledgements
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